Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 3/20 | 0.50 |
| ▸ | MMP2 | P08253 | 1/20 | 0.49 |
| ▸ | MMP9 | P14780 | 1/20 | 0.49 |
| ▸ | MMP8 | P22894 | 1/20 | 0.49 |
| ▸ | MMP13 | P45452 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | HPGD | P15428 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.46 |
| ▸ | CHEK2 | O96017 | 7/20 | 0.45 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.43 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.43 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.43 |
| ▸ | MPL | P40238 | 1/20 | 0.41 |
| ▸ | GLA | P06280 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2564176 | 0.85 | ALDH1A1 (0.54) | ERN1MMP2MMP9MMP8MMP13 | |
| SCHEMBL14930162 | 0.85 | ALDH1A1 (0.55) | ERN1KDM4EALDH1A1HPGDKMT2A | |
| SCHEMBL22840334 | 0.85 | ERN1 (0.37) | ERN1KDM4E | |
| SCHEMBL14916768 | 0.80 | ERN1 (0.51) | ERN1ALDH1A1HPGD | |
| SCHEMBL14930122 | 0.80 | ERN1 (0.59) | ERN1HPGD | |
| SCHEMBL22840577 | 0.79 | CA12 (0.40) | ERN1KDM4EALDH1A1HPGD | |
| SCHEMBL7943519 | 0.78 | KDM4E (0.61) | MMP2MMP9MMP8MMP13KDM4E | |
| SCHEMBL28296530 | 0.77 | GSK3B (0.43) | ERN1ALDH1A1HPGDKMT2AADORA2A | |
| SCHEMBL21475689 | 0.77 | CHEK2 (0.37) | ERN1CHEK2 | |
| SCHEMBL22840599 | 0.77 | LMNA (0.46) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110172051-B | IRE-1 alpha inhibitors | 复星弘创(苏州)医药科技有限公司 | 2023-03-07 | — | — | CN | disclosed |
| US-11337956-B2 | IRE-1α inhibitors | FOSUN ORINOVE PHARMATECH, INC. (CN) | 2022-05-24 | — | — | US | disclosed |
| US-11337956-B2 | IRE-1α inhibitors | FOSUN ORINOVE PHARMATECH, INC. (CN) | 2022-05-24 | — | — | US | disclosed |
| EP-3799870-A1 | IRE-1A INHIBITORS | Fosun Orinove Pharmatech, Inc. (CN) | 2021-04-07 | — | — | EP | disclosed |
| EP-3799870-A1 | IRE-1A INHIBITORS | Fosun Orinove Pharmatech, Inc. (CN) | 2021-04-07 | — | — | EP | disclosed |
| EP-3409276-B1 | IRE-1A INHIBITORS | FOSUN ORINOVE PHARMATECH INC (CN) | 2020-12-30 | — | — | EP | disclosed |
| EP-3409276-B1 | IRE-1A INHIBITORS | FOSUN ORINOVE PHARMATECH INC (CN) | 2020-12-30 | — | — | EP | disclosed |
| US-20190314330-A1 | IRE-1ALPHA INHIBITORS | FOSUN ORINOVE PHARMATECH, INC. (CN) | 2019-10-17 | — | — | US | disclosed |
| US-20190314330-A1 | IRE-1ALPHA INHIBITORS | FOSUN ORINOVE PHARMATECH, INC. (CN) | 2019-10-17 | — | — | US | disclosed |
| US-10357475-B2 | IRE-1α inhibitors | FOSUN ORINOVE PHARMATECH, INC. (CN) | 2019-07-23 | — | — | US | disclosed |
| US-9693992-B2 | IRE-1α inhibitors | MANNKIND CORPORATION (US) | 2017-07-04 | — | — | US | disclosed |
| US-9040714-B2 | IRE-1α inhibitors | MANNKIND CORPORATION (US) | 2015-05-26 | — | — | US | disclosed |
| US-9040714-B2 | IRE-1α inhibitors | MANNKIND CORPORATION (US) | 2015-05-26 | — | — | US | disclosed |
| US-20150141424-A1 | IRE-1alpha INHIBITORS | FOSUN ORINOVE PHARMATECH, INC. (CN) | 2015-05-21 | — | — | US | disclosed |
| US-20150141424-A1 | IRE-1alpha INHIBITORS | FOSUN ORINOVE PHARMATECH, INC. (CN) | 2015-05-21 | — | — | US | disclosed |
| US-20150141424-A1 | IRE-1alpha INHIBITORS | FOSUN ORINOVE PHARMATECH, INC. (CN) | 2015-05-21 | — | — | US | disclosed |
| US-20130116247-A1 | IRE-1alpha INHIBITORS | MANNKIND CORPORATION (US) | 2013-05-09 | — | — | US | disclosed |
| US-20130116247-A1 | IRE-1alpha INHIBITORS | MANNKIND CORPORATION (US) | 2013-05-09 | — | — | US | disclosed |
| EP-2555768-A2 | IRE-1 INHIBITORS | MannKind Corporation (US) | 2013-02-13 | — | — | EP | disclosed |
| WO-2011127070-A2 | IRE-1α INHIBITORS | MANNKIND CORPORATION (US) | 2011-10-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150141424-A1 | IRE-1alpha INHIBITORS | ERN1, XBP1, ERN2 | ERN1 1/4885MMP2 3541/4885MMP9 3998/4885 |
| US-11337956-B2 | IRE-1α inhibitors | XBP1, ERN1, ERN2 | ERN1 2/4885MMP2 3789/4885MMP9 3705/4885 |
| US-20190314330-A1 | IRE-1ALPHA INHIBITORS | ERN1, XBP1, ERN2 | ERN1 1/4885MMP2 3541/4885MMP9 3998/4885 |
| US-10357475-B2 | IRE-1α inhibitors | XBP1, ERN1, ERN2 | ERN1 2/4885MMP2 3789/4885MMP9 3705/4885 |
| US-20130116247-A1 | IRE-1alpha INHIBITORS | ERN1, XBP1, ERN2 | ERN1 1/4885MMP2 3715/4885MMP9 4118/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.